Hudry Delphine, Le Guellec Solenn, Meignan Samuel, Bécourt Stéphanie, Pasquesoone Camille, El Hajj Houssein, Martínez-Gómez Carlos, Leblanc Éric, Narducci Fabrice, Ladoire Sylvain
Inserm, U1192-Protéomique Réponse Inflammatoire Spectrométrie de Masse-PRISM, Lille University, F-59000 Lille, France.
Department of Gynecologic Oncology, Oscar Lambret Center, F-59000 Lille, France.
Cancers (Basel). 2022 Oct 29;14(21):5332. doi: 10.3390/cancers14215332.
Epithelial ovarian cancers (EOC) are often diagnosed at an advanced stage with carcinomatosis and a poor prognosis. First-line treatment is based on a chemotherapy regimen combining a platinum-based drug and a taxane-based drug along with surgery. More than half of the patients will have concern about a recurrence. To improve the outcomes, new therapeutics are needed, and diverse strategies, such as immunotherapy, are currently being tested in EOC. To better understand the global immune contexture in EOC, several studies have been performed to decipher the landscape of tumor-infiltrating lymphocytes (TILs). CD8+ TILs are usually considered effective antitumor immune effectors that immune checkpoint inhibitors can potentially activate to reject tumor cells. To synthesize the knowledge of TILs in EOC, we conducted a review of studies published in MEDLINE or EMBASE in the last 10 years according to the PRISMA guidelines. The description and role of TILs in EOC prognosis are reviewed from the published data. The links between TILs, DNA repair deficiency, and ICs have been studied. Finally, this review describes the role of TILs in future immunotherapy for EOC.
上皮性卵巢癌（EOC）通常在晚期伴发癌转移时被诊断出来，预后较差。一线治疗基于铂类药物和紫杉烷类药物联合化疗方案并辅以手术。超过半数的患者会担心复发。为改善治疗效果，需要新的治疗方法，目前多种策略，如免疫疗法，正在EOC中进行测试。为更好地了解EOC中的整体免疫情况，已开展了多项研究来解析肿瘤浸润淋巴细胞（TIL）的情况。CD8 + TIL通常被认为是有效的抗肿瘤免疫效应细胞，免疫检查点抑制剂可能会激活它们来排斥肿瘤细胞。为综合EOC中TIL的相关知识，我们根据PRISMA指南对过去10年发表在MEDLINE或EMBASE上的研究进行了综述。从已发表的数据中回顾了TIL在EOC预后中的描述和作用。研究了TIL、DNA修复缺陷和免疫检查点之间的联系。最后，本综述描述了TIL在EOC未来免疫治疗中的作用。
